Loading asset research
Denali Therapeutics Inc. Common Stock
DNLINasdaq · USD · StocksQuote as of · Exchange session not verified$21.08
-1.52%
Today
DNLI
Loading 1D prices…
Market cap
$3.4B
Volume
1.2M
52w high
$27.3052w low
$12.58Company profile
Denali Therapeutics Inc. Common Stock
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
South San Francisco, CA, United States
Employees
503
Fiscal year end
1231
CIK
1714899
Session & valuation
Open$21.65
Previous close$21.40
Day high$21.79
Day low$21.06
30-day avg. volume1.3M
Outstanding shares159.8M
Diluted EPS-$2.97
Latest annual period
P/E (trailing)-7.10
P/E (forward)-8.72
Price / book4.03
Beta1.00
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| TARSTarsus Pharmaceuticals Inc. Common Stock | $3.7B | $451.4M | -14.62% | -$1.59 | -2.28% | Buy |
| ADPTAdaptive Biotechnologies Corporation Common Stock | $3.9B | $277M | -21.48% | -$0.39 | -0.17% | Buy |
| IOVAIovance Biotherapeutics Inc. Common Stock | $3.9B | $263.5M | -148.39% | -$1.09 | +5.90% | Buy |
| RLAYRelay Therapeutics Inc. Common Stock | $4.1B | $15.4M | -1800.58% | -$1.61 | -0.11% | Buy |
| BEAMBeam Therapeutics Inc. Common Stock | $2.5B | $139.7M | -57.24% | -$0.81 | -1.60% | Buy |